Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease

Clinical Pharmacokinetics

Volumn 53, Issue 7, 2014, Pages 637-648

  Goyal, Navin ^a   Beerahee, Misba ^b   Kalberg, Chris ^a   Church, Alison ^a   Kilbride, Sally ^b   Mehta, Rashmi ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLACEBO; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; ETHNICITY; FEMALE; HUMAN; LIMIT OF QUANTITATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; POPULATION MODEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEVERE RENAL IMPAIRMENT; SMOKING; AREA UNDER THE CURVE; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG INTERACTION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903709945     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0143-4     Document Type: Article

References (21)

1. Celli BR, MacNee W. ATS ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46. (Pubitemid 38807371)
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011. http://www.goldcopd.org/uploads/users/ files/GOLD-Report-2011-Feb21.pdf. Accessed 28 Jan 2014.
3. World Health Organisation. Chronic obstructive pulmonary disease (COPD): burden of COPD. 2011. http://www.who.int/respiratory/copd/burden/en/index.html. Accessed 28 Jan 2014.
4. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-46.
5. Feldman G, Walker RR, Brooks J, et al. Safety and tolerability of the GSK573719/vilanterol combination in patients with COPD. Am J Respir Crit Care Med. 2012;185:A2938.
6. Celli B, Crater, G, Kilbride, S, et al. Once-daily umeclidinium/ vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014; in press.
7. Hankinson JL, Kawut SM, Shahar E, et al. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the Multi-Ethnic Study of Atherosclerosis (MESA) lung study. Chest. 2010;137:138-45.
8. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-87. (Pubitemid 29036522)
9. Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC Chronic Dyspnea Scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med. 2010;10:32.
10. European Medicines Agency. Guideline on reporting the results of population pharmacokinetic analyses. 2007.
11. Food and Drug Administration. Guidance for industry: population pharmacokinetics. 1999.
12. Ahn JE, Karlsson MO, Dunne A, et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401-21.
13. Holford N. The visual predictive check: superiority to standard diagnostic (Rorschach) plots. Presented at the Population Approach Group in Europe (PAGE), Pamplona, Spain. 2005; Abstract 738.
14. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36:425-38. (Pubitemid 29317490)
15. Bieth B. Population pharmacokinetics of QVA149, the fixed dose combination of indacaterol maleate and glycopyrronium bromide in chronic obstructive pulmonary disease (COPD) patients. Presented at the Population Approach Group in Europe (PAGE), Glasgow Scotland. 2013; Abstract 2800.
16. Connolly MJ, Crowley JJ, Charan NB, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest. 1995;108:401-6.
17. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155-63.
18. Kelleher D, Hardes K, et al. Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). Eur Respir J. 2013;42(Suppl. 57):881s.
19. Mehta R, Hardes K, Kelleher D, et al. Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK). Eur Respir J. 2013;42(Suppl. 57):751s.
20. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504. (Pubitemid 33151426)
21. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11:371-80.